News | Heart Valve Technology | June 27, 2025

Foldax Announces One-Year Data on Tria Mitral Valve

The India clinical trial results were presented at New York Valves and concurrently published in Journal of the American College of Cardiology.

Foldax Announces One-Year Data on Tria Mitral Valve

Top view of TRIA Mitral Valve


June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling one-year results from the India Clinical Trial of the TRIA Mitral Valve, showing a good safety profile, sustained hemodynamic performance, and statistically significant improvement in patient quality of life. These are the first one-year outcomes ever presented for a multicenter clinical study of a polymer heart valve worldwide. Results were presented  at New York Valves 2025,the annual conference organized by the Cardiovascular Research Foundation (CRF), and concurrently published in the Journal of the American College of Cardiology (JACC).

Key one-year results from the trial showed:

  • No valve-related mortality or reinterventions
  • >50% reduction in mean gradient (9.7 mmHg to 4.5 mmHg) and >90% increase in  effective orifice area (0.9 cm² to 1.5 cm²), the highest reported in similar surgical mitral valve studies
  • 24-point improvement in KCCQ score (57.5 to 81.9) and 65% increase in Six-Minute Walk Test distance (298.1 m to 494.8 m), indicating significant improvement in quality of life

The prospective, multicenter trial enrolled 67 patients aged 19 to 67 across eight sites in India, with an average age of 42.  Notably, 64% were women, and of these, nearly half were of childbearing age, a significantly larger percentage than typically seen in clinical studies. Seventy-three percent of patients had rheumatic heart disease. 

Foldax Tria Mitral Valve
Side view of the Tria Mitral Valve

“It is exciting to see the positive clinical outcomes associated with this novel polymer valve,” said Isaac George, M.D., Surgical Director of the Heart Valve Center at Columbia University. “This new type of valve sets out to reimagine how a device can address clinical needs that are underserved by current valve solutions.”

“I am proud to be the principal investigator in India for this groundbreaking trial and represent the highly esteemed clinical investigators who participated in the study,” said Kaushal Pandey, M.D., Principal Investigator of the TRIA Mitral Valve India Clinical Trial and Cardiac Surgeon at P.D. Hinduja Hospital in Mumbai. “The TRIA Mitral Valve provides hope for Indian patients—including younger patients and many women of childbearing age—for whom current valve options often fall short.”

Foldax’s vision for its novel polymer heart valves is to address the limitations of tissue and mechanical options by making its valves durable, with the future goal of avoiding a requirement for lifelong anticoagulation. TRIA valves incorporate a proprietary polymer—LifePolymer™ —formulated to be calcium-resistant, biostable and biocompatible. The novel polymer material enables TRIA valves to be robotically produced, which is designed to increase manufacturing efficiency and maximize product quality and precision. 

“These results validate our strategy of taking heart valve therapy to a new level by bringing innovation to a platform of products that will help patients globally,” said Ken Charhut, CEO of Foldax. 

The Journal of the American College of Cardiology (JACC) publication can be viewed at: https://doi.org/10.1016/j.jacc.2025.06.017

For more information on the TRIA Mitral Valve and Foldax, visit www.Foldax.com.

*NOTE: The TRIA Mitral Valve is approved for use in India by CDSCOThe TRIA Mitral Valve is for investigational use only and is not available for commercial sale in the U.S.

 


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
Subscribe Now